Things To Know This higher research figure reflects a specific study population under supervision, not a general target
DPP-4 inhibitors carry a minimal risk of hypoglycemia and gastrointestinal symptoms
concurrently, SHBG levels rose, free testosterone decreased, and ovarian volume showed a directional decrease
The three-receptor mechanism of retatrutide is not just a marketing claim
Both albiglutide and dulaglutide received FDA approval for the treatment of T2DM in 2014, with dulaglutide having an additional indication since 2020 to reduce the risk of major adverse cardiovascular events (MACE) in adults with T2DM and established cardiovascular disease or multiple cardiovascular risk factors [ Table 2 ]
In January 2024, The Obesity Society, Obesity Action Coalition and Obesity Medicine Association released a joint statement against the use of compounded and counterfeit medications